Full Year Capital Guidance Lowered; Production Guidance Increased Highlights: Generated cash from operating activities of $1,013 million, Non-GAAP Cash ...

Protagonist Therapeutics, Inc.Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy ...

The US Food and Drug Administration appears poised to continue with a plan to ban prescription fluoride supplements at a time ...

Identifying the correct uveitis type can help reveal underlying systemic infections, neoplastic conditions, and other ...

Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials. Read my analysis ...

A 64-year-old woman presented to an outside provider with 5 days of left eye “burning, itching, redness and blurry vision” ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

A rare Guillain-Barré syndrome recurrence caused nausea with no motor symptoms but was treated successfully with intravenous ...

One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Preclinical results in animals have demonstrated protection against mpox and other orthopoxviruses, supporting further clinical evaluation ... A copy of the presentation will be posted in the ...

Doping, Misinformation, and the Community Burden of Performance-Enhancing Substances. Health, 17, 869-887. doi: 10.4236/health.2025.177057 . Recent studies show that the overuse of ...